Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Silman

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Bjpsych Open|September 4, 2023
Clozapine and Sweet's syndrome: case reportApphia Bunting, Daniel Silman, Minesh Karia, et al.
Vaccine|August 7, 2017
Vaccines against Ebola virusNavin Venkatraman, Daniel Silman, Pedro M Folegatti, et al.
Bjpsych Open|December 22, 2025
Longitudinal validation of the Maudsley 3-item visual analogue scale (M3VAS): a new, brief, patient-reported outcome measure of depressionDaniel Silman, Maria Elena Middag, Anthony J Cleare, et al.
Journal of Psychopharmacology (Oxford, England)|June 20, 2025
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy volunteersMutahira Qureshi, Daniel Silman, Romayne Gadelrab, et al.
Trials|November 6, 2025
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPERShrushma Loi, Paras Joshee, Ryan Ottridge, et al.
Science Translational Medicine|September 28, 2018
Prime and target immunization protects against liver-stage malaria in miceAnita Gola, Daniel Silman, Adam A Walters, et al.
Wellcome Open Research|April 13, 2026
Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsDaniel Silman, Amy Flaxman, Mehreen Datoo, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Journal of Affective Disorders|January 31, 2026
Personal recovery as outcome measure in mental health research: A meta-analysis on the sensitivity to change properties of the Recovery Assessment ScaleT A D Pelgrim, K Kleine Schaars, R Moldovan, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Bjpsych Open|September 4, 2023
Clozapine and Sweet's syndrome: case reportApphia Bunting, Daniel Silman, Minesh Karia, et al.
Vaccine|August 7, 2017
Vaccines against Ebola virusNavin Venkatraman, Daniel Silman, Pedro M Folegatti, et al.
Bjpsych Open|December 22, 2025
Longitudinal validation of the Maudsley 3-item visual analogue scale (M3VAS): a new, brief, patient-reported outcome measure of depressionDaniel Silman, Maria Elena Middag, Anthony J Cleare, et al.
Journal of Psychopharmacology (Oxford, England)|June 20, 2025
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy volunteersMutahira Qureshi, Daniel Silman, Romayne Gadelrab, et al.
Trials|November 6, 2025
A randomised controlled trial to evaluate the clinical and cost-effectiveness of Stimulant compared with Non-stimulant medication for adults with Attention-deficit/hyperactivity disorder and a history of Psychosis or biPolar disordER: SNAPPERShrushma Loi, Paras Joshee, Ryan Ottridge, et al.
Science Translational Medicine|September 28, 2018
Prime and target immunization protects against liver-stage malaria in miceAnita Gola, Daniel Silman, Adam A Walters, et al.
Wellcome Open Research|April 13, 2026
Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsDaniel Silman, Amy Flaxman, Mehreen Datoo, et al.
The Lancet. Infectious Diseases|April 24, 2020
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialPedro M Folegatti, Mustapha Bittaye, Amy Flaxman, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
Journal of Affective Disorders|January 31, 2026
Personal recovery as outcome measure in mental health research: A meta-analysis on the sensitivity to change properties of the Recovery Assessment ScaleT A D Pelgrim, K Kleine Schaars, R Moldovan, et al.
Pageof 2